Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2018-08-27 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
第二届监事会第二次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Shenzhen BGI Genomics Co., Ltd. It details the meeting procedures, voting results, and approvals related to the 2018 semi-annual report, profit distribution plan, fundraising usage report, related party transaction limits, and asset impairment provisions. The document does not contain the actual semi-annual financial report or detailed financial statements but rather the Supervisory Board's approval and confirmation of these reports and plans. The document length is 2238 characters, which is relatively short and consistent with an announcement rather than a full report. It also references that the actual reports are published separately on the official disclosure website. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is an official announcement of Supervisory Board resolutions and approvals related to interim reports and other corporate matters, not the report itself.
2018-08-27 Chinese
2018年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled "深圳华大基因股份有限公司 2018 年半年度报告摘要" which translates to "Shenzhen BGI Genomics Co., Ltd. 2018 Semi-Annual Report Summary." It contains detailed financial data for the first half of 2018, including revenue, net profit, cash flow, earnings per share, and asset information. It also discusses business operations, strategic initiatives, shareholder information, and other comprehensive management commentary. The document length is about 11,962 characters, indicating it is a substantive report rather than a brief announcement. The content and structure align with a comprehensive interim or quarterly financial report rather than a full annual report or a simple earnings release. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2018
2018-08-27 Chinese
2018年半年度报告披露提示性公告
Report Publication Announcement Classification · 100% confidence The document is a short announcement (442 characters) stating that the company's 2018 semi-annual report (half-year report) has been approved and published on an official disclosure website. It does not contain the actual financial data or the report itself, but rather informs investors where to find the full report. According to the 'MENU VS MEAL' rule, such a brief notice about the report's disclosure is classified as a Report Publication Announcement (RPA), not the Interim/Quarterly Report (IR) itself.
2018-08-27 Chinese
关于2018年半年度计提资产减值准备的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Shenzhen BGI Genomics Co., Ltd. regarding the provision for asset impairment for the half-year period ending June 30, 2018. It details the reasons, scope, amounts, and approval procedures for the impairment provision. The document explicitly states that the impairment provision is unaudited and includes opinions from the board, independent directors, and supervisory board. The document length is 2583 characters, which is relatively short and focused on a specific accounting adjustment rather than a full financial report. It is not a full interim or annual report, nor is it a certification or regulatory filing. It is a specific announcement about an accounting provision related to the half-year period, which aligns with a Regulatory Filing (RNS) as it does not contain comprehensive financial statements or detailed financial analysis typical of an Interim Report (IR). It also does not fit other categories like Earnings Release or Audit Report. Therefore, the best classification is Regulatory Filings (RNS).
2018-08-27 Chinese
2018年半年度报告
Interim / Quarterly Report Classification · 95% confidence The document is titled "深圳华大基因股份有限公司 2018 年半年度报告全文" which translates to "BGI Genomics Co., Ltd. 2018 Semi-Annual Report Full Text." It contains detailed financial data, company business overview, accounting data, and management statements for the half-year period ending June 30, 2018. The document includes sections such as "经营情况讨论与分析" (Management Discussion and Analysis), financial indicators, and detailed business descriptions. The length is substantial (15,000 characters), and it contains actual financial statements and substantive financial data, not just an announcement or summary. The document is clearly a comprehensive interim/quarterly report covering a period shorter than a full fiscal year, consistent with the definition of an Interim / Quarterly Report (IR). Therefore, the correct classification is IR with high confidence. H1 2018
2018-08-27 Chinese
中信证券股份有限公司关于公司2018年半年度跟踪报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "2018年半年度跟踪报告" which translates to "2018 Half-Year Tracking Report". It is issued by a sponsoring institution (中信证券股份有限公司) regarding Shenzhen BGI Genomics Co., Ltd. The content includes detailed oversight and compliance information related to the company's governance, shareholder commitments, shareholding restrictions, and other regulatory compliance matters. The document is comprehensive and contains substantive information about the company's performance and governance for a half-year period. It is not a brief announcement or a certification letter but a detailed report covering a period shorter than a full fiscal year, consistent with an Interim / Quarterly Report. Therefore, the appropriate classification is Interim / Quarterly Report (IR). H1 2018
2018-08-27 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.